OCT 16·SEC EDGARLow
Foff Erin Pennock sold $124K of MPLT
Foff Erin Pennock (Chief Medical Officer) sold 15,355 shares of MapLight Therapeutics, Inc. (MPLT) at $8.08 ($0.12M total) on 2026-10-15.
StockNASDAQ · US · USDHealthcare · Biotechnology
$MPLT
MapLight Therapeutics, Inc.
AlphAI earnings readSecond quarter 2026 · AUG 13MapLight reported positive Phase 2 ZEPHYR results for ML-007C-MA in schizophrenia, continued enrollment in the Phase 2 VISTA ADP trial, and ended the quarter with $351.3 million in cash, cash equivalents and investments.Verdict: mixedRead →
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Price · $MPLTvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $MPLT in the last 7 days.
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $1.1M 6 txs
Hanson Kristopher1× · $73K
10b5-1 share of filings0%
Top stories · $MPLTMore →
OCT 16·SEC EDGAR
Kroeger Christopher A. sold $595K of MPLT
Kroeger Christopher A. (Chief Executive Officer) sold 73,691 shares of MapLight Therapeutics, Inc. (MPLT) at $8.08 ($0.60M total) on 2026-10-15.
AUG 18·SEC EDGAR
Catalyst4, Inc. purchased $50.1M of MPLT (indirect holdings)
Catalyst4, Inc. purchased 4,400,000 indirectly-held shares of MapLight Therapeutics, Inc. (MPLT) at $11.38 ($50.07M total) on 2026-08-14.
MPLT sentiment & insider activity
Recent MPLT coverage spans insider activity, corporate actions and market movers.
In the last 30 days, MPLT insiders filed 6 SEC Form 4 transactions — no purchases and 6 sales ($1.1M). The most active reporter was Hanson Kristopher, General Counsel, with 1 filing.
What's driving MPLT
The insider sale may signal personal liquidity needs or lack of confidence, but the amount is modest.
The insider sale may signal reduced confidence or simply portfolio rebalancing.
The filing signals a large 10% owner adding to MapLight Therapeutics, but it is not a fundamental update like guidance or trial data.
The PIPE provides runway through 2028 but is dilutive, so near-term price action may hinge on whether investors view the financing as sufficient versus dilution risk.
The filing indicates MPLT is raising capital via a private placement structure (common shares plus pre-funded warrants), which can be dilutive and may pressure near-term sentiment.
AlphAI scores every news story that mentions MPLT with an AI model for sentiment and relevance, and aggregates insider trades from MapLight Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $MPLT
Score
Foff Erin Pennock sold $124K of MPLT
Foff Erin Pennock (Chief Medical Officer) sold 15,355 shares of MapLight Therapeutics, Inc. (MPLT) at $8.08 ($0.12M total) on 2026-10-15.
1 min readKroeger Christopher A. sold $595K of MPLT
Kroeger Christopher A. (Chief Executive Officer) sold 73,691 shares of MapLight Therapeutics, Inc. (MPLT) at $8.08 ($0.60M total) on 2026-10-15.
1 min readCatalyst4, Inc. purchased $50.1M of MPLT (indirect holdings)
Catalyst4, Inc. purchased 4,400,000 indirectly-held shares of MapLight Therapeutics, Inc. (MPLT) at $11.38 ($50.07M total) on 2026-08-14.
1 min readMapLight Raises $150 M PIPE To Fund CNS Pipeline
MapLight Therapeutics (MPLT) priced a $150 million PIPE, selling 9.2M shares at $11.38 and 4.0M pre-funded warrants at $11.3799, exercisable at $0.0001 with no expiration. Proceeds will fund CNS drug ML-007C-MA, including VISTA Phase 2 in Alzheimer’s disease psychosis and ZEPHYR-2 Phase 3 in schizophrenia. Closing expected Aug. 14, 2026.
2 min readMapLight Therapeutics, Inc. (MPLT): Reported positive results from the potentially registrational Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia, supporting advancement into a Phase 3…
MapLight Therapeutics, Inc. (MPLT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Reported positive results from the potentially registrational Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia, supporting advancement into a Phase 3 ZEPHYR-2 trial Continued advancement of ML-007C-MA in ADP, with enrollment ongoing in the Phase 2 VISTA trial and
6 min readMapLight Therapeutics, Inc.: MapLight Therapeutics Announces $150 Million Private Placement Financing
MapLight Therapeutics (Nasdaq: MPLT) announced a $150 million PIPE private placement. It will sell 9,197,887 common shares at $11.38 and pre-funded warrants for up to 3,983,168 shares at $11.3799, with an exercise price of $0.0001. Proceeds will fund ML-007C-MA (VISTA Phase 2 and ZEPHYR-2 Phase 3) and working capital. Expected close Aug. 14, 2026.
4 min readCatalyst4, Inc. purchased $15.3M of MPLT (indirect holdings)
Catalyst4, Inc. purchased 1,209,225 indirectly-held shares of MapLight Therapeutics, Inc. (MPLT) at an average of $12.66 ($10.74–$13.00, $15.31M total) across 4 trades over 2026-07-28 to 2026-07-30.
2 min readTop Biotech Gainers: KNSA Soars On Q2 Results, TRIB, OPK On Watch, MPLT On The Mend?
Biotech gainers included Trinity Biotech (TRIB), which rose 36% after Q2 results and a one-for-thirty reverse ADS split to regain Nasdaq bid compliance. OPKO Health (OPK) gained 33% on Q2 revenue of $163.5M and softer Q3/full-year guidance. Kiniksa (KNSA) jumped 25% after raising 2026 net product revenue outlook to $980M-$995M. MapLight (MPLT) rebounded 24% after mixed Phase 2 schizophrenia data. ProMIS (PMN) rose 24% on interim Alzheimer’s data; Prelude (PRLD) rose 19% without specific news.
7 min readStocks Fall from Early Highs as Chipmakers Retreat
Stocks slipped from early highs as chipmakers and AI-infrastructure shares fell. The iShares Semiconductor ETF (SOXX) fell over 3%, with Sandisk (SNDK) down more than 11% and AMD and Western Digital down over 6%. Crude dropped about 6%, lifting T-notes and lowering 10-year breakeven inflation. Software stocks rose; Workday gained over 8%.
6 min readMapLight Therapeutics director Troy Cox buys $148,702 in shares By Investing.com
MapLight Therapeutics director Troy Cox bought 15,620 shares of MPLT for $148,702 on July 28, 2026, at a weighted average price of $9.52. The stock later traded around $12.31. The article also notes multiple analyst price target cuts and rating changes tied to MapLight’s Phase 2 ZEPHYR trial results.
3 min read